Reviewer’s report

Title: Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway

Version: 0 Date: 16 Jun 2017

Reviewer: Tao Che

Reviewer’s report:

In this manuscript, the authors investigated the anti-cancer effect of DT. The results are clear. But given that the authors have already published a very similar work early this year (Wu CY et al, Oncotarget, 2017), the work here loses lots of novelty. Although the authors tried to combine it with radiation and detected some other responding proteins, there are still several major issues:

1. Based on Fig.1 and 2, can you say there is no cooperative activity between DT and radiation? Because there is very small difference between "5 uM DT" and "5 uM DT and 5 Gy IR", the small difference seems to be the result of IR.

2. As said before, most of the results here have been shown in a previous paper they published and don't know why they didn't cite the paper. Although they detected increased expression level of r-H2AX and p-ATM. It doesn't necessarily mean they are involved in DT-induced anti-cancer effect. Is it possible they are just side effects of DT treatment? Blocking this pathway will restore the cell migration?

3. The authors didn't use normal cells as a control? Are these events also occurring in normal cells?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal